Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDProtagonist Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 4 | -$0.18 | $0.56 | $0.10 |
| Q2 2025 | 2 | -$1.60 | $0.12 | -$0.53 |
| Q3 2025 | 2 | -$1.71 | $0.12 | -$0.57 |
| Q4 2025 | 2 | -$1.31 | $0.09 | -$0.44 |
Protagonist Therapeutics, Inc. Earnings Date And Information
Protagonist Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.54 earnings per share for the quarter, topping analysts' consensus estimates of $-0.59 by $0.05. The company had revenue of 4.68 M for the quarter and had revenue of 60.00 M for the year. Protagonist Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.39 diluted earnings per share) and currently has a price-to-earnings ratio of 13.26. Protagonist Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Protagonist Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.59 | -$0.54 | 0.05 | $3.11 M | $4.68 M |
| 08/06/2024 | Q2 2024 | -$0.50 | -$0.50 | 0 | $3.14 M | $4.17 M |
| 05/07/2024 | Q1 2024 | $1.19 | $3.41 | 2.22 | $254.95 M | |
| 02/27/2024 | Q4 2023 | $0.03 | $0.45 | 0.42 | $60.00 M | |
| 11/02/2023 | Q3 2023 | -$0.68 | -$0.58 | 0.1 | $0 | |
| 08/03/2023 | Q2 2023 | -$0.65 | -$0.68 | -0.03 | $0 | |
| 05/04/2023 | Q1 2023 | -$0.69 | -$0.62 | 0.07 | $0 | |
| 03/15/2023 | Q4 2022 | -$0.67 | -$0.64 | 0.03 | $0 | |
| 11/08/2022 | Q3 2022 | -$0.94 | -$0.62 | 0.32 | $0 | |
| 08/04/2022 | Q2 2022 | -$0.99 | -$0.83 | 0.16 | $460,000 | $859,000 |
| 05/05/2022 | Q1 2022 | -$0.43 | $25.72 M | |||
| 02/28/2022 | Q4 2021 | -$0.79 | -$0.77 | 0.02 | $8.62 M | |
| 11/03/2021 | Q3 2021 | -$0.67 | -$0.70 | -0.03 | $1.74 M | $10.29 M |
| 08/04/2021 | Q2 2021 | -$0.62 | -$0.69 | -0.07 | $5.17 M | $2.27 M |
| 05/04/2021 | Q1 2021 | -$0.57 | -$0.54 | 0.03 | $6.19 M | |
| 03/10/2021 | Q4 2020 | -$0.47 | -$0.48 | -0.01 | $5.65 M | |
| 11/04/2020 | Q3 2020 | -$0.61 | -$0.21 | 0.4 | $2.87 M | $13.11 M |
| 08/06/2020 | Q2 2020 | -$0.57 | -$0.59 | -0.02 | $2.95 M | $6.22 M |
| 05/07/2020 | Q1 2020 | -$0.64 | -$0.72 | -0.08 | $3.65 M | |
| 03/10/2020 | Q4 2019 | -$0.64 | -$0.63 | 0.01 | $2.72 M |
Protagonist Therapeutics, Inc. Earnings: FAQ's
When is Protagonist Therapeutics, Inc.'s earnings date?
Protagonist Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
Did Protagonist Therapeutics, Inc. beat their earnings estimates last
quarter?
In the previous quarter, Protagonist Therapeutics, Inc. (:PTGX) reported $-0.54 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.59 by $0.05.
How can I listen to Protagonist Therapeutics, Inc.'s earnings conference
call?
The conference call for Protagonist Therapeutics, Inc.'s latest earnings report can be listened to online.
How can I read Protagonist Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Protagonist Therapeutics, Inc.'s latest earnings report can be read online.
How much revenue does Protagonist Therapeutics, Inc. generate each year?
Protagonist Therapeutics, Inc. (:PTGX) has a recorded annual revenue of $60.00 M.
How much profit does Protagonist Therapeutics, Inc. generate each year?
Protagonist Therapeutics, Inc. (:PTGX) has a recorded net income of $60.00 M. Protagonist Therapeutics, Inc. has generated $-1.39 earnings per share over the last four quarters.
What is Protagonist Therapeutics, Inc.'s price-to-earnings ratio?
Protagonist Therapeutics, Inc. (:PTGX) has a price-to-earnings ratio of 13.26 and price/earnings-to-growth ratio is 9.21.